Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910

Rudick RA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911–923

Sandborn WJ et al (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353(18):1912–1925

Phan-Ba R et al (2012) MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83(2):224–226

Butzkueven H et al (2014) Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2013-306936

Piehl F et al (2011) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 31(Suppl 3):289–293

Oturai AB et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16(3):420–423

Melin A et al (2012) Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 259(6):1215–1221

Outteryck O et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2):207–211

Fernandez O et al (2012) Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 259(9):1814–1823

Sangalli F et al (2010) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(3):299–302

Prosperini L et al (2010) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 31(3):303–307

Putzki N et al (2010) Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17(1):31–37

Holmen C et al (2011) A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 17(6):708–719

Bloomgren G et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870–1880

Kappos L et al (2012) Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI(R) observational program (TOP) (P04.134). Neurology 78:P04.134

Spelman (2012) Comparison of natalizumab and interferon-beta/glatiramer acetate efficacy using a propensity-matched registry data (S133). Mult Scler J 18(4 suppl):9–53

Hutchinson M et al (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256(3):405–415